Swami Umang, Swick Brian, Zakharia Yousef, Milhem Mohammed
Department of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA 52242, USA.
Department of Dermatology and Pathology, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA 52242, USA.
Case Rep Oncol Med. 2019 Mar 7;2019:4683531. doi: 10.1155/2019/4683531. eCollection 2019.
Talimogene laherparepvec is a novel, genetically engineered, oncolytic herpes virus approved for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. It is administered as an intralesional injection. However, if the lesion continues to persist, it presents with a clinical challenge as when to stop treatment. Herein, we present two cases from our institution wherein the disease appeared to be persistent radiologically; however, on pathological excision, there was no evidence of disease and patients continue to be in durable remission after stopping treatment.
Talimogene laherparepvec是一种新型的、基因工程改造的溶瘤性疱疹病毒，已被批准用于局部治疗初次手术后复发的黑色素瘤患者不可切除的皮肤、皮下和淋巴结病变。它通过瘤内注射给药。然而，如果病变持续存在，何时停止治疗就会带来临床挑战。在此，我们展示了我们机构的两个病例，其中从影像学上看疾病似乎持续存在；然而，病理切除后，没有疾病证据，患者在停止治疗后仍处于持久缓解状态。
